NCT00018031View on ClinicalTrials.gov

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Hepatitis CHIV Infections
Interventions
DRUG

Peginterferon alfa-2b

Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously

DRUG

Ribavirin

Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00018031 - Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients | Biotech Hunter | Biotech Hunter